Julie Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie Pham has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Feng Zhang
Howard Hughes Medical Institute, Cambridge, USA
4 shared publications - Rhiannon K. Macrae
Howard Hughes Medical Institute, Cambridge, USA
4 shared publications - Blake Lash
Howard Hughes Medical Institute, Cambridge, USA
2 shared publications - Daniel Strebinger
Howard Hughes Medical Institute, Cambridge, USA
2 shared publications Mirco J. Friedrich
Howard Hughes Medical Institute, Cambridge, USA
2 shared publicationsCatherine C. Liu
Howard Hughes Medical Institute, Cambridge, USA
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Nature Communications
In vitro–reconstituted Drosophila Arc capsids deliver gene editors to dystrophic muscle
The intracellular delivery of therapeutic macromolecules remains a major challenge in biomedicine. Capsid-forming proteins are one promising vehicle, but to date, these have required cellular assembly or rely on fusogens for cell entry, limiting their scalability and utility. Here we reconstitute the Drosophila melanogaster Arc1 (dArc1) retroelement-derived capsid entirely from purified recombinant protein components and in vitro transcribed RNA, creating a fully defined, cell-free assembled protein nanoparticle system. We engineered the dArc1 RNA-binding domain to efficiently encapsulate both mRNA payloads and Cas9 ribonucleoproteins. We show that dArc1 capsids bind mammalian cells through a direct interaction with the surface receptor SORCS2. Leveraging this interaction, we demonstrate that intramuscular injection of dArc1 capsids carrying Cas9 gene editors achieves up to 18% exon skipping and restores dystrophin expression in muscle fibers of mdx mice, a model of Duchenne muscular dystrophy. This work demonstrates the potential of in vitro-assembled protein nanoparticles for delivery of molecular cargoes.
- 4 November 2026
- Published by Springer Nature in Nature Communications
Open AccessIn vitro–reconstituted Drosophila Arc capsids deliver gene editors to dystrophic muscle
The intracellular delivery of therapeutic macromolecules remains a major challenge in biomedicine. Capsid-forming proteins are one promising vehicle, but to date, these have required cellular assembly or rely on fusogens for cell entry, limiting their scalability and utility. Here we reconstitute the Drosophila melanogaster Arc1 (dArc1) retroelement-derived capsid entirely from purified recombinant protein components and in vitro transcribed RNA, creating a fully defined, cell-free assembled protein nanoparticle system. We engineered the dArc1 RNA-binding domain to efficiently encapsulate both mRNA payloads and Cas9 ribonucleoproteins. We show that dArc1 capsids bind mammalian cells through a direct interaction with the surface receptor SORCS2. Leveraging this interaction, we demonstrate that intramuscular injection of dArc1 capsids carrying Cas9 gene editors achieves up to 18% exon skipping and restores dystrophin expression in muscle fibers of mdx mice, a model of Duchenne muscular dystrophy. This work demonstrates the potential of in vitro-assembled protein nanoparticles for delivery of molecular cargoes.
- Open Access
- 17 December 2025
- Published by Springer Nature in Nature
- Vol. 650 (8101) , 481-489
Transient hepatic reconstitution of trophic factors enhances aged immunity
Ageing erodes human immunity, in part by reshaping the T cell repertoire, leading to increased vulnerability to infection, malignancy and vaccine failure 1–3 . Attempts to rejuvenate immune function have yielded only modest results and are limited by toxicity or lack of clinical feasibility 1,3–5 . Here we show that the liver can be transiently repurposed to restore age-diminished immune cues and improve T cell function in aged mice. These immune cues were found by performing multi-omic mapping across central and peripheral niches in young and aged animals, leading to the identification of Notch and Fms-like tyrosine kinase 3 ligand (FLT3L) pathways, together with interleukin-7 (IL-7) signalling, as declining with age. Delivery of mRNAs encoding Delta-like ligand 1 (DLL1), FLT3L and IL-7 to hepatocytes expanded common lymphoid progenitors, boosted de novo thymopoiesis without affecting haematopoietic stem cell (HSC) composition, and replenished T cells while enhancing dendritic cell abundance and function. Treatment with these mRNAs improved peptide vaccine responses and restored antitumour immunity in aged mice by increasing tumour-specific CD8 + infiltration and clonal diversity and synergizing with immune checkpoint blockade. These effects were reversible after dosing ceased and did not breach self-tolerance, in contrast to the inflammatory and autoimmune liabilities of recombinant cytokine treatments 6,7 . These findings underscore the promise of mRNA-based strategies for systemic immune modulation and highlight the potential of interventions aimed at preserving immune resilience in ageing populations.
- 17 December 2025
- Published by Springer Nature in Nature
- Vol. 650 (8101) , 481-489
Open AccessTransient hepatic reconstitution of trophic factors enhances aged immunity
Ageing erodes human immunity, in part by reshaping the T cell repertoire, leading to increased vulnerability to infection, malignancy and vaccine failure 1–3 . Attempts to rejuvenate immune function have yielded only modest results and are limited by toxicity or lack of clinical feasibility 1,3–5 . Here we show that the liver can be transiently repurposed to restore age-diminished immune cues and improve T cell function in aged mice. These immune cues were found by performing multi-omic mapping across central and peripheral niches in young and aged animals, leading to the identification of Notch and Fms-like tyrosine kinase 3 ligand (FLT3L) pathways, together with interleukin-7 (IL-7) signalling, as declining with age. Delivery of mRNAs encoding Delta-like ligand 1 (DLL1), FLT3L and IL-7 to hepatocytes expanded common lymphoid progenitors, boosted de novo thymopoiesis without affecting haematopoietic stem cell (HSC) composition, and replenished T cells while enhancing dendritic cell abundance and function. Treatment with these mRNAs improved peptide vaccine responses and restored antitumour immunity in aged mice by increasing tumour-specific CD8 + infiltration and clonal diversity and synergizing with immune checkpoint blockade. These effects were reversible after dosing ceased and did not breach self-tolerance, in contrast to the inflammatory and autoimmune liabilities of recombinant cytokine treatments 6,7 . These findings underscore the promise of mRNA-based strategies for systemic immune modulation and highlight the potential of interventions aimed at preserving immune resilience in ageing populations.
- Open Access
- 12 August 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (7) , 1121-1125
Targeted delivery of diverse biomolecules with engineered bacterial nanosyringes
The Photorhabdus virulence cassette is a microbial nanosyringe that can be engineered to deliver protein cargos into human cells. Here we further modify this system to incorporate exogenous cargos and targeting moieties in vitro. We show that this method, termed SPEAR, enables loading of different types of cargo (including folded ribonucleoproteins and single-stranded DNA) and targeting of defined cell types both in vitro and in vivo.
- 12 August 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (7) , 1121-1125
Open AccessTargeted delivery of diverse biomolecules with engineered bacterial nanosyringes
The Photorhabdus virulence cassette is a microbial nanosyringe that can be engineered to deliver protein cargos into human cells. Here we further modify this system to incorporate exogenous cargos and targeting moieties in vitro. We show that this method, termed SPEAR, enables loading of different types of cargo (including folded ribonucleoproteins and single-stranded DNA) and targeting of defined cell types both in vitro and in vivo.
- Open Access
- 7 May 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (5) , 759-770
Evolution-guided protein design of IscB for persistent epigenome editing in vivo
Naturally existing enzymes have been adapted for a variety of molecular technologies, with enhancements or modifications to the enzymes introduced to improve the desired function; however, it is difficult to engineer variants with enhanced activity while maintaining specificity. Here we engineer the compact Obligate Mobile Element Guided Activity (OMEGA) RNA-guided endonuclease IscB and its guiding RNA (ωRNA) by combining ortholog screening, structure-guided protein domain design and RNA engineering, and deep learning-based structure prediction to generate an improved variant, NovaIscB. We show that the compact NovaIscB achieves up to 40% indel activity (~100-fold improvement over wild-type OgeuIscB) on the human genome with improved specificity relative to existing IscBs. We further show that NovaIscB can be fused with a methyltransferase to create a programmable transcriptional repressor, OMEGAoff, that is compact enough to be packaged in a single adeno-associated virus vector for persistent in vivo gene repression. This study highlights the power of combining natural diversity with protein engineering to design enhanced enzymes for molecular biology applications.
- 7 May 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (5) , 759-770
Open AccessEvolution-guided protein design of IscB for persistent epigenome editing in vivo
Naturally existing enzymes have been adapted for a variety of molecular technologies, with enhancements or modifications to the enzymes introduced to improve the desired function; however, it is difficult to engineer variants with enhanced activity while maintaining specificity. Here we engineer the compact Obligate Mobile Element Guided Activity (OMEGA) RNA-guided endonuclease IscB and its guiding RNA (ωRNA) by combining ortholog screening, structure-guided protein domain design and RNA engineering, and deep learning-based structure prediction to generate an improved variant, NovaIscB. We show that the compact NovaIscB achieves up to 40% indel activity (~100-fold improvement over wild-type OgeuIscB) on the human genome with improved specificity relative to existing IscBs. We further show that NovaIscB can be fused with a methyltransferase to create a programmable transcriptional repressor, OMEGAoff, that is compact enough to be packaged in a single adeno-associated virus vector for persistent in vivo gene repression. This study highlights the power of combining natural diversity with protein engineering to design enhanced enzymes for molecular biology applications.